Exploiting transferrin receptor for delivering drugs across the blood-brain barrier
Open accessAbstract
Delivery of large molecule drugs across the blood brain barrier is increasingly being seen as an achievable goal. Several technologies have been described where following peripheral administration the molecules can be detected in the brain. Foremost amongst these technologies are antibodies against the transferrin receptor. Following a burst of publications in the very early twenty first century, excitement seemed to wane as contrary data started to emerge. Over the last few years antibodies against transferrin receptor have again started to raise hopes of successful drug delivery to the central nervous system, as protein engineering techniques have allowed a more detailed understanding of the antibody properties necessary for successful transport across the blood brain barrier.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Tf-TfR system is considered a promising target to enhance the uptake of drugs that are specifically conjugated to Tf to be recognized by the TfR and to facilitate uptake in multidrug-resistant tumor cells.
“Therefore, the Tf–TfR system is considered a promising target to enhance the uptake of drugs that are specifically conjugated to Tf to be recognized by the TfR and to facilitate uptake in, i.e. multidrug-resistant tumor cells [104].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061 · see citing works
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · see citing works
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622 · see citing works
Drug and gene targeting to the brain with molecular trojan horses
Pardridge, W. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd725 · Cited by 439 · see citing works
Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., & Starzyk, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4771 · Cited by 402 · see citing works
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358 · see citing works
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 357 · see citing works
Mechanisms of Brain Iron Transport: Insight into Neurodegeneration and CNS Disorders
Mills, E., Dong, X.-P., Wang, F., & Xu, H. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.09.140 · Cited by 309 · see citing works
Lee, H., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287 · see citing works
Brain-specific expression of an exogenous gene after i.v. administration
Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221450098 · Cited by 273 · see citing works
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H. O., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 270 · see citing works
Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells
Descamps, L., Dehouck, M., Torpier, G., & Cecchelli, R. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.270.4.h1149 · Cited by 168 · see citing works
Sade, H., Baumgartner, C., Hugenmatter, A., Moessner, E., Freskgård, P., & Niewoehner, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096340 · Cited by 148 · see citing works
Kissel, K., Hamm, S., Schulz, M., Vecchi, A., Garlanda, C., & Engelhardt, B. (1998) · Histochemistry and Cell Biology · doi:10.1007/s004180050266 · Cited by 130 · see citing works
Boado, R. J., Zhou, Q.-H., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900235k · Cited by 117 · see citing works
Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor
Zhang, Y., & Pardridge, W. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082974 · Cited by 110 · see citing works
Lee, H. J., Zhang, Y., Zhu, C., et al. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200202000-00010 · Cited by 78 · see citing works
Paris‐Robidas, S., Émond, V., Tremblay, C., Soulet, D., & Calon, F. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071027 · Cited by 69 · see citing works
Lee, H. J., Boado, R. J., Braasch, D. A., et al. (2002) · PubMed · Cited by 56 · see citing works
Characterization of lectin-mediated brain uptake of HIV-1 GP120
Banks, W. A., & Kastin, A. J. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981115)54:4 · Cited by 49 · see citing works
Widespread expression of an exogenous gene in the eye after intravenous administration.
Zhu, C., Zhang, Y., & Pardridge, W. M. (2002) · PubMed · Cited by 44 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Moos T, Morgan EH. Evidence for low molecular weight, non-transferrin- bound iron in rat brain and cerebrospinal fluid. J Neurosci Res 1998;54:486-94.
Cited by
Sorted by citations
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268 · see citing works
- Authors
- Paterson, J., & Webster, C. I.
- Corresponding author
- Webster, Carl I.
- Venue
- Drug Discovery Today Technologies
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 20
- Pages
- 49-52
- ISSN
- 1740-6749 (ISSN-L)
- OpenAlex
- W2543298877
- Cited by
- 87
- References
- 21
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 4 · 2017: 1
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drug Discovery Today Technologies (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- transferrin receptor, blood-brain barrier, brain drug delivery, large molecule drugs, protein engineering, antibody properties, transcytosis
- MeSH terms
- Animals, Antibodies, Blood-Brain Barrier, Pharmaceutical Preparations, Humans, Receptors, Transferrin, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
